A therapeutic update on cutaneous leishmaniasis

Journal of the College of Physicians and Surgeons Pakistan

Volumn 13, Issue 8, 2003, Pages 471-476

  ul Bari, Arfan ^a   ber Rahman, Simeen ^b  

^a PAF Hosopital ^*  (Pakistan)

^b Rawalpindi General Hospital   (Pakistan)

Author keywords

Amphotericin B; Cutaneous leishmaniasis; Pentavalent antimonials; Topical treatment

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; CHLOROQUINE; CLOTRIMAZOLE; CYCLOSPORIN; DAPSONE; FLUCONAZOLE; HERBACEOUS AGENT; IMIDAZOLE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; METRONIDAZOLE; MICONAZOLE; MILTEFOSINE; MONOCLONAL ANTIBODY; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; PENTOXIFYLLINE; RECOMBINANT ANTIGEN; RECOMBINANT INTERFERON; RIFAMPICIN; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; WR 279396;

ABDOMINAL PAIN; ANAPHYLAXIS; ANOREXIA; ANTIPROTOZOAL ACTIVITY; BRADYCARDIA; CLINICAL FEATURE; CRYOSURGERY; DRUG EFFICACY; DRUG EXCRETION; DRUG RESPONSE; DRUG SAFETY; ECG ABNORMALITY; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; JOINT STIFFNESS; LIVER TOXICITY; LONG QT SYNDROME; MALAISE; MYALGIA; NAUSEA; NEPHROTOXICITY; PANCREATITIS; REVIEW; RHABDOMYOLYSIS; SKIN LEISHMANIASIS; TACHYCARDIA; THROMBOPHLEBITIS; TREATMENT FAILURE; URINARY EXCRETION; VOMITING;

ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, CUTANEOUS; PROTOZOAN VACCINES; TREATMENT OUTCOME; VACCINATION;

EID: 0042884140     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. World Health Organization (WHO). Report of Expert Committee. The leishmaniases: World Health Organ Tech Rep Ser 701, 1984.
2. Mujtaba G, Khalid M. Cutaneous leishmaniasis in Multan, Pakistan. Int J Dermatol 1998; 37: 843-6.
3. Raja KM Khan AA, Hameed A, Rahman SB. Unusual clinical variants of cutaneous leishmaniasis in Pakistan. Br J Dermatol 1998; 139: 111-3.
4. Grevelink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996; 34: 257-72.
5. World Health Organization. WHO Report of the Workshop of Chemotherapy of Old World Cutaneous Leishmaniasis. Geneva: WHO, 1983.
6. Kubba R, Al-Gindan Y. Leishmaniasis. Dermatol Clin 1989; 7: 331-51.
7. Bryceson ADM. Tropical dermatology. Br J Dermatol 1976; 94: 223-6.
8. Stratigos JD. New aspects on cutaneous leishmaniasis. Dermatosen 1980; 5: 139-48.
9. Kikuth W, Schmidt H. Contribution to the progress of antimony therapy of Kala-azar. Chinese Med J 1937; 52: 425-32.
10. Durand P, Benmussa S, Caruana M. Traitement du Kala-azar par un nouveau campose stibie: 2, 168 RP (premiers resultats). Bull Mem Soc Med Bop Paris 1946;62: 399-409.
11. British Pharmacopeia. London: HMSO, 1973:439-40.
12. Voller A, Shaw JJ, Bryant C. The effects of two antimony drugs on the in vitro metabolism of radioactive glucose forms of Leishmania tropica. Ann Trop Med Parasitol 1963;57: 404-8.
13. Berman JD, Waddell D, Hanson BC. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985; 27: 916-20.
14. Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infec Dis 1980; 142: 83-6.
15. Khan AA, Iqbal Z, Hameed A, Mirza SH, Rahman SB, Tahir A, et al. Clinical efficacy of pentavalent antimonial compound (meglumine antimonate) and dapsone in the treatment of cutaneous leishmaniasis. Pak Armed Forces Med J 1997; 47: 33-6.
16. Asher AM, Khalid H. Efficacy of allopurinol compared with pentostam in the treatment of Old World cutaneous leishmaniasis. J Coll Physicians Surg Pak 2001; 1: 367-70.
17. Kern F, Pederson JK. Leishmaniasis in the United States: a report of ten cases in military personnel.J Am Med Assoc 1973; 226: 872-4.
18. Ghosh S. Evaluation of sodium stibogluconate in the treatment of cutaneous leishmainasis in Syria. Curr Med Res Opin 1979; 6: 280-3.
19. Chulay JD, Spencer HG, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34: 702-9.
20. Ballou WR, McChain JR, Gardon DM, Shanks GD, Andujar J, Berman JD, et al. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987; 2: 13-6.
21. Alkhawaja AM, Larbi E. Al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular vs intralesional administration. Ann Trop Med Parasitol 1997; 91: 899-905.
22. Bryceson ADM, Chulay JD, Mugambi M, Were JB, Gachihi G, Chunge CN, et al. Visceral leishmaniasis unresponsive to antimonial drugs II: response to high-dose sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg 1985; 79: 705-14.
23. Marsden PD, Sampaio RNR, Carvalho EM, Veiga JPT, Costa JLM, Lianos-Cuentas EA. High continuous antimony therapy in two patients with unresponsive mucocutaneous leishmaniasis. Am J Trop Med Hyg 1985; 34: 710-3.
24. Oster CN, Chulay JD, Hendricks LD, McGarvy PB, Takafuji EJ, Pamplan CL, et al. American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 1985; 34: 856-60.
25. World Health Organization. Antimonials. Large scale failure in leishmaniasis alarming. TDR News 1990: 34.
26. Hentzer B, Kobayasi T. The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann Trop Med Parasital 1977; 71: 157-66.
27. Bryceson AD. Diffuse cutaneous leishmaniasis: treatment. Trans R Soc Trop Med Hyg 1970; 64: 369-79.
28. Sen Gupta PC. Chemotherapy of leishmanial diseases: a resume of recent researches. Indian Med Gazette 1953; 88: 20-35.
29. Nacher M, Couppie P, Carme B, Clyti E, Sainte Marie D, Guibert P, et al. Influence of meteorological parameters on the clinical presentation of cutaneous leishmaniasis in French Guiana and on the efficacy of pentamidine treatment of the disease. Ann Trop Med Parasitol 2002; 96: 773-80.
30. Lai A, Fat EJ, Vrede MA, Soetosenojo RM, Lai A, Fat RF. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 2002; 41: 796-800.
31. Bryceson ADM. Pentamidine-induced diabetes mellitus. East Afr Med J 1968; 45: 110-7.
32. Lieber-Mbomeyo A, Lipsker D, Milea M, Heid E. Rhabdomyolysis induced by pentamidine (Pentacarinat) during treatment of cutaneous leishmaniasis: 2 cases. Ann Dermatol Venereol 2002; 129: 50-2.
33. Kubba R, Al-Gindan Y, El-Hassan AM, Omer AHS. Ketoconazole in cutaneous leishmaniasis: results of a pilot study. Saudi Med J 1986; 7: 596-604.
34. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 21: 891-5.
35. Berman JD, Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
36. Weinrauch L, Livshin R, El-Ow J. Cutaneous leishmaniasis treatment with ketoconazole. Cutis 1983; 32: 288-9.
37. Urcuyo FG, Zaias N. Oral ketoconazole in the treatment of leishmaniasis. Int J Dermatol 1982; 21 :414-6.
38. Jollife DS. Cutaneous leishmaniasis from Belize: treatment with ketoconazole. Clin Exp Dermatol 1986; 11: 62-8.
39. Abahusein A, Larbi EB, Al-Khawajah A, Al-Gindan Y, Jain S. Evaluation of topical ketoconazole in cutaneous leishmaniasis. East Afr Med J 1992; 69: 14-9.
40. Macnair AL, Gascoigne E, Heap J. Hepatitis and ketoconazole therapy. Br Med J 1981; 283: 1058-60.
41. Van den Enden E, Campel A, Stevens A. Treatment of cutaneous leishmaniasis with oral itraconazole. Int J Dermatol 1994; 33: 285-6.
42. Pearson JK, Sawick S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol 1975; 111: 1343-4.
43. Beltran HF, Gutierrez FM, Biagi FF. Treatment of Mexican cutaneous leishmaniasis with metronidazole. Bull Soc Pathol Exot 1967; 70: 61.
44. Belehu A, Naffs B, Touw-langendijk E. Failure of metronidazole treatment in Ethiopian mucocutaneous leishmaniasis. Br J Dermatol 1978; 99: 421-2.
45. Bryceson ADM. Leishmaniasis. In: Wyngaarden JB, Smith LH Jr , editors. Cecil textbook of medicine. Edinburgh: Churchill Livingstone; 1980:815-8.
46. Maegrath B, (edi). Clinical tropical diseases. 7th ed. London: Blackwell Scientific Publication; 1980:184.
47. Ganor S. The treatment of leishmaniasis residuals with local injections of amphotericin B. Dermatol Int 1967; 6: 141-3.
48. Giri OP. Amphotericin B therapy in kala-azar. J Indian Med Assoc 1993; 91: 91-3.
49. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326: 741-4.
50. Selim MM, Kandil E. Rifampicin in the treatment of cutaneous leishmaniasis. J Kuwait Med Assoc 1972; 6: 159-63
51. Dogra J, Bhupender BL, Shyam NN. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986; 25: 398-400.
52. Wyler DJ, Marsden PD. Leishmaniasis. In: Warren KS, Mahmoud AAF, (edi). Tropical and geographical medicine. New York: McGrawHill; 1984: 270-80.
53. Guena MFV, Marsden PD, Cuba CC, Barreto AC. Further trials of nifurtimox in mucocutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75: 335-8.
54. Hoare CA. Early discoveries regarding the parasites of oriental sore. Trans Roy Soc Trop Med Hyg 1938; 32: 67-92.
55. Currie MA. Treatment of cutaneous leishmaniasis by curretage. Br med J 1983; 287: 1105-6.
56. Azab AS, Kamal MS, El-Hagar MS, Metawaa BA, Hindway DS. Early surgical treatment of cutaneous leishmaniasis. J Dermatol Surg Oncol 1983; 9: 1007-12.
57. Griffiths WAD, Croft SL. Cutaneous leishmaniasis. Postgrad Doctor Mid East 1980; 3: 388-94.
58. Berman JD, Nera FK. Effect of temperature on multiplication of leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 1981; 149: 302-18.
59. Junaid AJN. Treatment of cutaneous leishmaniasis with infra-red heat. Int J Dermatol 1986; 25: 470-2.
60. Mutinga MJ, Mingola EN. Alternate treatment of cutaneous leishmaniasis. East Afr Med J 1974; 51: 68-8.
61. Bassiony A, El-Mashad M, Talaat M, Kutty K, Metaawa B. Cryotherapy in cutaneous leishmaniasis. Br J Dermatol 1982; 107: 467-74.
62. Al-Gindan Y, Kubba R, El-Hassan AM, Omar AHS, Kutty NK, Saeed MB. Dissemination in cutaneous leishmaniasis: lymph node involvement. Int J Dermatol 1989; 28: 248-54.
63. Sharquie KE, Al-Talib KKA, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119: 53-7.
64. Kellum RE. Treatment of cutaneous leishmaniasis with an intralesional antimony drug (Pentostam®). J Am Acad Dermatol 1986; 15: 620-2.
65. Bogenrieder T, Lehn N, Landthaler M, Stolz W. Treatment of old world cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a dermojet device. Dermatology 2003; 206: 269-72.
66. Hussain AB, Amanullah, Dil AS, Kakar F, Sadaruddin A. The efficacy of intralesional treatment of cutaneous leishmaniasis with glucantime. Pak J Med Res 2002; 41: 54-7.
67. Al-Qubati Y. Cutaneous leishmaniasis from Yemen: treatment with intralesional injection of sodium stibogluconate with local anesthetic. Saudi Med J 1997; 18: 433-4.
68. Brenner S. Topical treatment with imidazoles for cutaneous leishmaniasis. Isr Med Sci 1985; 15: 620-2.
69. Larbi EM, Alkhawajah AM, Al-Gindan Y, Jain S, Abahusain A, Al-Zayer A. A randomized, double-blind clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the Eastern Province of Saudi Arabia. Am J Trop Med Hyg 1995; 52: 166-8.
70. El-On J, Jacobos GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988; 4: 76-81.
71. El-On J, Messer G. Leishmania major: antileishmanial activity of methylbenzethonium chloride. Am J Trop Med Hyg 1986; 35: 1110-6.
72. El-Safi SH, Murphy AG, Bryceson ADM, Neal RA. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg 1990; 84: 690-1.
73. Faghihi G, Tavakoli-Kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003 ; 28: 13-6.
74. Zerehsaz F, Beheshti S, Rezaian GR, Joubeh S. Cutaneous leishmaniasis: what about a new, inexpensive, effective, topical herbal remedy? J Med Liban 2001; 49: 143-5.
75. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002 ; 66: 147-51.
76. Frankenburg S, Glick D, Klaus S, Barenholz Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob Agents Chemother 1998; 42: 3092-6.
77. Gamier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002; 3: 538-44.
78. Pareek SS. Combination of sodium stibogluconate and rifampicin in cutaneous leishmaniasis. Int J Dermatol 1984; 23: 70-1.
79. Livshin R, El-On J, Weinrauch CL, Even-Paz Z. Therapeutic effect of rifampicin and isoniazid against Leishmania major. Int J Dermatol 1983; 22: 61.
80. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41: 521-4.
81. Momeni AZ, Aminjavaheri M. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur J Dermatol 2003; 13: 40-3.
82. Bafica A, Oliveira F, Freitas LA, Nascimento EG, Barral A. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol 2003; 42: 203-7.
83. Jacinto C, Pedro L, Castellanos A. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987; 1: 401-4.
84. Seaman J. Open field trial of short course of liposomal amphotericin B in complicated visceral leishmaniasis. Am J Trop Med Hyg 1993; 49: 274-7.
85. Squires KA. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon gamma. Am J Trop Med Hyg 1993; 42: 666-9.
86. Arana B, Rizzo N, Diaz A. Chemotherapy of cutaneous leishmaniasis: a review. Med Microbiol Immunol (Berl) 2001; 190: 93-5.
87. Amaral VF, Teva A, Oliveira-Neto MP, Silva AJ, Pereira MS, Cupolillo E, et al. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem Inst Oswaldo Cruz 2002; 97:1041-8.
88. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002; 20: 3292-3303.
89. Mayrink W, Santos GC, Toledo Vde P, Guimaraes TM, Machado-Coelho GL, Genaro O, et al. Vaccination of C57BL/10 mice against cutaneous leishmaniasis using killed promastigotes of different strains and species of Leishmania. Rev Soc Bras Med Trop 2002; 35: 125-32.
90. Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber F, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania amazonensis vaccine plus antimonial. Int J Dermatol 2002 ; 41: 73-8.